MedQuist investor Costa Brava puts forth slate of nominees for election to board

By Lisa Kerner

Charlotte, N.C., Oct. 23 - MedQuist, Inc. investors led by Costa Brava Partnership III LP filed a preliminary proxy statement with the Securities and Exchange Commission regarding the solicitation of proxies for the election of Andrew R. Siegel, Seth W. Hamot, Douglas M. Gleason, Douglas E. Linton and Alok Mohan to the company's board of directors at the next annual meeting of stockholders.

The filers, not including Andrew R. Siegel, are the beneficial owners of 1,938,821 shares, or 5.2% of MedQuist's common stock. Siegel beneficially owns 2,000 shares, or less than 1% of the company's issued and outstanding common shares, according to a schedule 13D filing with the SEC.

It was previously reported that Costa Brava filed a complaint against MedQuist in order to compel it to hold an annual meeting of stockholders by Dec. 15 and to hold an election for all seats on the board of directors at that meeting. The complaint was filed in the Superior Court of New Jersey, a previous SEC filing stated.

As a result, MedQuist was ordered to appear before the court on Nov. 16 to show why it should not be ordered to hold the meeting and election.

MedQuist is a Mt. Laurel, N.J.-based medical transcription technology and services company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.